Microbioz India, July 2023 | 51 Our next product was the multiple framing camera (SIM) which incorporated a novel 8-way beam splitter in a small footprint, whilst still maintaining an f2.8 aperture, plus an innovative additional optical split to share the same viewpoint with other auxiliary imaging devices, such as a spectrograph or streak camera. Over the years this product has evolved to allow 16 channels, double shot image intensifiers, gigabyte interface, optional canon mount interface and sophisticated velocity trap triggering. All additions have been developed as a result of customer feedback. The Queens Award for Innovation in 2011 was awarded to the company in recognition of the innovations in the SIM camera. Director - Wayne Smethurst continued “In 2007 we developed a Trajectory Tracker system, that allowed the predictive tracking of a projectile in flight. While we were not the first to market with this product, our innovations, reliability, and support has made this product the world leader in this marketplace. We have and will continue to develop and improve this product”. Technical Director and Co-founder - Keith Taylor added “Part of our original roadmap was to develop an Ultra-high-speed video camera. In partnership with the UK Science and Technology Facilities Council. From this project we developed the sensor that is used on the Kirana Camera. The camera has the fastest sensor at the highest resolution and frame storage. Currently the Kirana is capable of 7 million frames per second, at 924x764 with 180 frames making it the fastest camera in its class. The effort of the team won another Queens Award for innovation in 2016”. Concluding, Wai Chan said “In the 20 years since Specialised Imaging’s humble beginnings with 4 people working from a garage in Tring UK, we have grown to today operate from a purpose-built office/factory with 30 staff in Pitstone, UK plus offices in Temecula USA, Munich Germany, and Beijing China. The company also has specialist sales channels spread across the world, from Australia, to South Africa and Japan. Specialised Imaging business has been and will continue to be based around offering the highest quality cameras for our customer’s applications, backed with our vast experience and expertise. The success of our business is a result of the immense dedication of all the people associated with us, from our employees right through the supply chain, who work to provide products to the standards that our customer’s demand. With our own image sensor and camera development teams, we are going to continue redefining ultra-high-speed cameras to provide engineers and scientists worldwide with better tools to analyse their fundamental research”. VitaDAO Launches VITAFAST Tokens, Revolutionizing Governance in Longevity Research Story source/Credit: VitaDAO Pictured: Professor Viktor Korolchuk, Reader in Molecular Cell Biology at Newcastle University. itaDAO, the global community accelerating research and development in longevity science, is pleased to announce the launch of the VITA-FAST tokens. This marks the firstever opportunity for token holders to directly influence longevity research, setting a new precedent in the field of decentralized science (DeSci). The VITA-FAST tokens, which allow holders to make decisions on IP licensing, set experiment priorities, and govern research on autophagy, have been met with overwhelming interest. The initial token sale was 2000% oversubscribed, with $620k in bids, demonstrating the public's eagerness to participate in scientific research. This groundbreaking initiative is spearheaded by the esteemed Korolchuk Lab, led by renowned cellular biologist Prof. Viktor Korolchuk. The lab's work focuses on autophagy, a process vital to cellular health and implicated in ageing and various diseases. The launch of VITA- FAST tokens not only provides financial support for this cutting-edge research but also fosters a community-driven approach to biomedical research. Alex Dobrin, head of community at VitaDAO, said, "This is the next phase in the evolution of decentralized patient communities, to directly contribute to, govern, and be rewarded for progressing valuable longevity research." V Product Launches
Microbioz India, July 2023 | 52 VitaDAO engaged its community in the token sale by using a newly launched crowdsales platform developed by Molecule AG, which developed the original IP-NFT platform for capturing IP in web3, and is a strategic contributor to VitaDAO. "The success of the VITA-FAST token sale is a testament to VitaDAO's innovative approach to integrating public participation into scientific research. It also underscores the potential of decentralized finance (DeFi) to fill in the gaps left by traditional funding agencies", as noted by Paul Kohlhaas, CEO of Molecule. Professor Matthew Grenby, Pro-Vice-Chancellor for Research and Innovation at Newcastle University added "It’s great to see this cutting-edge research going out into the world, and we are excited to be at the forefront of biomedical research funding. We look forward to supporting Molecule AG and VitaDAO with development of this novel platform and commercialisation of their IP". The VITA-FAST token offering marks a significant step forward for VitaDAO as it begins advancing its early research assets toward their next development milestones. The VITA-FAST tokens will provide ongoing options for funding for the Korolchuk Lab as it advances its research program. About VitaDAO VitaDAO is a global community for the acceleration of research and development (R&D) in longevity science and the extension of human health- and lifespan. VitaDAO achieves this through funding and incubating research and researchers using the tools of decentralised science ("DeSci") to reduce the time for therapeutic development and, ultimately, bring aging under medical control. VitaDAO, with a community of over 9000 enthusiasts, researchers, and contributors, deployed so far over $4M USD in 17+ projects researching the diseases of ageing, with a focus on cellular biology and the repair of damage associated with the hallmarks of aging. All researchers are welcome to apply for funding, including professors, post-docs, research scientists, and even students. EMBL and ZEISS enter long-term strategic partnership Story source/Credit: ZEISS Accelerating the development of imaging technology to advance life science research The European Molecular Biology Laboratory (EMBL) and ZEISS have entered a long-term strategic partnership. The collaboration aims to close the gap between early-stage imaging technology development and its application in life science research. Through this collaborative approach, users of the EMBL Imaging Centre and related EMBL imaging services will have access to the latest microscopy technologies and expertise from ZEISS. At the same time, the research carried out at EMBL and projects by Imaging Centre users will provide ZEISS with invaluable insights into new applications and opportunities for market-testing their most recent technology developments. Continuous collaboration The new agreement, negotiated with support from EMBL’s technology transfer arm EMBLEM, is based on the long-term collaborative interaction between EMBL and ZEISS and previous projectbased partnerships. For example, ZEISS recently supported the initial equipment for operations in the EMBL Imaging Centre and provided microscopy instruments for the EMBL mobile laboratories for field research. Product Launches
Microbioz India, July 2023 | 53 “EMBL and ZEISS have been working together fruitfully on multiple microscopy projects for decades, and we are excited to take the next step in our relations and give it a strategic perspective in this new framework agreement,” commented Jan Ellenberg, Head of the EMBL Imaging Centre. The long-term collaboration will allow the users of the Imaging Centre to get early access to the latest microscopy innovations from ZEISS. At the same time, regular strategic discussions will provide a unique opportunity for EMBL and ZEISS to engage in joint technology development, thereby making sure life scientists’ future needs for imaging technologies are taken into account for the development of the next generation of commercial microscopes. The EMBL Imaging Centre’s core mission is to provide access to and training in cutting-edge imaging technologies and to stimulate the ongoing development of these technologies. This offers a unique opportunity to take the partnership with ZEISS to a new level. Michael Albiez, Head of ZEISS Research Microscopy Solutions, stated: “This collaboration is creating new ways for both EMBL and ZEISS to interact and work together. The cutting-edge research performed in the EMBL Imaging Centre and EMBL as a whole will be an ideal testing and development environment for our next generation of imaging technologies.” Enabling future life science applications EMBL and ZEISS work together to make new technologies available as early as possible to users of the Imaging Centre and related EMBL services and thereby guide their development for future applications in the life sciences. The collaboration focuses on three areas: the joint development and application testing of new imaging technologies, joint activities in Open Data, and training. About ZEISS ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totalling 8.8 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2022). For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 13 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future. With over 40,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities (status: 31 March 2023). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG. About ZEISS Research Microscopy Solutions ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA and China. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment. About EMBL The European Molecular Biology Laboratory (EMBL) is Europe’s life sciences laboratory. Product Launches
Microbioz India, July 2023 | 54 We provide leadership and coordination for the life sciences across Europe, and our world-class fundamental research seeks collaborative and interdisciplinary solutions for some of society’s biggest challenges. We provide training for students and scientists, drive the development of new technology and methods in the life sciences, and offer state-of-theart research infrastructure for a wide range of experimental and data services. EMBL is an intergovernmental organisation with 28 member states, one associate member, and one prospective member. At our six sites in Barcelona, Grenoble, Hamburg, Heidelberg, Hinxton near Cambridge, and Rome, we seek to better understand life in its natural context, from molecules to ecosystems. Agilent Innovation Again Recognized with Multiple Scientists' Choice Awards Story source/Credit: Agilent Technologies Agilent 6475 Triple Quadrupole LC/MS System ighlighting leadership in cutting-edge mass spectroscopy solutions and outstanding customer service Agilent Technologies Inc.,has announced the receipt of three 2023 Scientists’ Choice Awards; Best New Spectroscopy Product of 2022, Analytical Science Video of the Year, Analytical Science Customer Service of the Year, and a Platinum Seal of Quality for their entire analytical HPLC systems. Announced on June 6th, 2023, at ASMS, these Scientists’ Choice Awards recognize the world’s most innovative and effective analytical science technologies, solutions, and focus on customers. The Best New Spectroscopy Product of 2022 was awarded to the Agilent 6475 Triple Quadrupole LC/MS System. The 6475 is a sensitive, robust, and versatile triple quadrupole mass spectrometer incorporating several technological advantages including the superheated Agilent Jet Stream (AJS) ion source, curved and tapered collision cell, heated hyperbolic quadrupoles, and ± 20 kV high-energy dynode detector system. “We would like to thank our loyal customers for voting for the Agilent 6475 Triple Quadrupole LC/MS System,” said Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division. “This is the latest evolution of our robust LC/MS/MS, incorporating instrument intelligence technologies such as early maintenance feedback, scheduled tune and check-tune, and intelligent secondary injection workflows that integrate seamlessly to help meet the challenges of our customers.” The Analytical Science Video of the Year award was presented to Professor Detlef Knappe from North Carolina State University, in collaboration with Agilent, for his video ‘Is our water safe to drink? Determining the quality of water.’ Discussing his work in analyzing contaminants in drinking water, Professor Detlef Knappe highlights how Agilent supported the development of the analytical methods he uses to identify and assess contaminants, including per- and polyfluoroalkyl substances (PFASs), enabling a better understanding of the routes of contamination and determining the potential safety of drinking water. In recognition of the achievement of consistently receiving positive feedback from scientists around the globe via reviews on the SelectScience website, Agilent Technologies also received the Analytical Science Customer Service of the Year. Additionally, based on the number of reviews and stars it has received on the Select Science website, Agilent also was awarded the SelectScience Platinum Seal of Quality for its HPLC and UHPLC range of systems which includes the 1220 Infinity II, 1260 Infinity II, 1260 Infinity II Prime, and the 1290 Infinity II LC systems. “These multiple, top class SelectScience awards, as voted on by Agilent users and customers, recognize Agilent’s commitment to exemplary customer service, support, and innovation,” commented Sudharshana Seshadri, vice president of Agilent’s Mass Spectroscopy, Liquid Chromatography and Automation division. H Product Launches
Microbioz India, July 2023 | 55 "Agilent has long played a role in helping our customers advance their research and testing, with our scientists and product managers developing some of the world's leading-edge technologies, and field engineers working side-by-side with customers, helping them to maximize their productivity. Together, we are bringing great science to life.” About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research Story source/Credit: Revvity, Inc he HIVE CLX Single-Cell RNAseq Solution integrates sample storage and single cell profiling into a robust, instrument-free workflow In collaboration with single cell genomics company, Honeycomb Biotechnologies (“Honeycomb”), Revvity (NYSE: RVTY) announced the launch of a suite of new solutions and services that expand the frontiers of single cell biology: the HIVE™ CLX Single-Cell RNAseq Solution, BeeNetPLUS analysis workflow, and for single cell researchers based in the United States, a new HIVE CLX Service offering. The HIVE CLX Single-Cell RNAseq Solution offers higher density single cell capture with integrated sample storage in an instrument-free workflow, making it easier for researchers to study rare and fragile cell types and better understand how the immune system fights allergens and pathogens, in addition to other applications. It is a significant upgrade to Honeycomb’s HIVE platform that was launched in collaboration with Revvity in 2021. “The HIVE CLX solution is uniquely designed to enable clinical researchers to overcome challenges often encountered in single cell studies. User-friendly sample capture and storage expands both the scope and geographic reach of single cell research, especially in areas such as innate immunology and infectious disease,” said Jim Flanigon, CEO of Honeycomb. “Our colleagues at Revvity share our goal of bringing single cell technology to a broader audience, so we’re excited to see our customers expand those boundaries with the HIVE CLX solution.” Larger, More Secure Sample Volumes Honeycomb’s HIVE CLX solution features 160,000 picowells within a single, high-density array that allows for as much as four times as many cells to be recovered per device as compared with the original HIVE™ scRNAseq Solution. T Product Launches
Microbioz India, July 2023 | 56 The premise is that more cells recovered translates to more transcripts processed, ultimately leading to more reliable, quality data that impacts health advances and biological insights across autoimmune research, oncology, neurology, developmental biology, transplant medicine and beyond. Any Cell. Anywhere. Anytime. By eliminating the need for specialized instrumentation, the HIVE CLX solution is well suited to support researchers working in remote or low-resource locations where sample storage and shipping requirements may be more complex. This includes studies involving emerging or evolving infectious diseases like HIV, malaria, tuberculosis and COVID-19, as well as distributed and longitudinal studies that involve multi-point sample collection. “The ability to understand human health and disease at the single-cell level is notoriously challenging, but an incredibly important pursuit in biological and clinical research,” said Arvind Kothandaraman, general manager of multi-omics and specialty diagnostics at Revvity. “We are pleased that the HIVE CLX solution is helping scientists of all backgrounds and experience levels access single cell RNAseq technology.” Cloud-based Data Analysis and Service from Single Cell Experts In addition to the HIVE CLX solution, Honeycomb has released its BeeNetPLUS cloudbased analysis workflow that simplifies and accelerates data interpretation of HIVE CLX results. With no coding or command line experience required, the BeeNetPLUS workflow reports on sequencing quality; cell, gene and transcripts recovery; cell-type annotation; differential expression; and marker gene plots. Researchers in the United States may now also take advantage of the HIVE CLX Service offering, made possible by the single cell experts at Honeycomb and Revvity. Beginning with one-on-one experimental design and ending with review of data with a bioinformatics expert, these sample-to-result concierge services benefit researchers working across a range of single cell applications. Further information on the HIVE CLX solution is available on Revvity's webpage, with additional protocols and technical information also available on the Honeycomb website. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. About Honeycomb Biotechnologies Honeycomb Biotechnologies develops technology to remove barriers and expand opportunities for single cell analysis in basic, translational, pre-clinical, and clinical research throughout the world. Founded by leading scientists at the Massachusetts Institute of Technology and the Broad Institute, Honeycomb is based in Waltham, MA, USA. PEAK Scientific launches new dedicated nitrogen solution Story source/Credit: Peak Scientific Instruments Ltd EAK Scientific have introduced the latest addition to their range of nitrogen gas generation solutions with the release of the Corona P 1010A. Product Launches
Microbioz India, July 2023 | 57 Designed by PEAK to meet the requirements of Corona charged aerosol detectors, the Corona 1010A delivers a high-purity, filtered nitrogen supply for applications requiring flows of up to 5 litres per minute at pressures up to 80psi. An evolution of the long-standing Corona 1010 nitrogen solution, the Corona 1010A is a standalone, on-demand nitrogen generator, designed to offer a space saving solution to fit in any laboratory. A cost-effective alternative to gas cylinders, the Corona 1010A reduces laboratory costs and carbon footprint by removing the need for repeated deliveries of gas cylinders. Gregor Thompson, PEAK Scientific’s Product Manager for the Corona 1010A, said, “We are delighted to have designed an upgrade to the existing Corona 1010 nitrogen generator to suit the needs of labs with Corona charged aerosol detectors or evaporative light scattering detectors. By including a built-in air compressor in the Corona 1010A, we have managed to streamline our customers’ workflow and workspace. PEAK’s Corona 1010A comes with a fullycomprehensive 1-year on-site warranty, subject to meeting the company’s terms of service. For more information on the Corona 1010A, visit PEAK Scientific’s website today About PEAK Scientific PEAK Scientific produces market-leading nitrogen, hydrogen and zero air systems mainly for the fields of LC-MS (Liquid Chromatography-Mass Spectrometry) and GC (Gas Chromatography). What differentiates us is our world-class technical support and ongoing service care throughout the generator’s lifespan, wherever you may be in the world. Synexa Life Sciences Joins CEPI in Advancing Global Epidemic Preparedness and Response Story source/Credit: Synexa Life Sciences Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces its membership in the Coalition for Epidemic Preparedness Innovations (CEPI) Central Lab Network (CLN). This strategic partnership represents a significant milestone in Synexa's commitment to global health security and its dedication to fostering collaboration and innovation in epidemic preparedness and response. The CLN is the largest global group using the same methods and materials to standardise and accelerate the evaluation of vaccines against epidemic and pandemic diseases. The CLN is a key enabler of CEPI’s 100 Days Mission, which aims to reduce vaccine development timelines to just 100 days, by helping researchers and regulators to evaluate the most promising vaccine candidates quickly and accurately when faced with a future ‘Disease X’ – a newly identified pathogen with epidemic or pandemic potential. Product Launches
Microbioz India, July 2023 | 58 Justin Devine, Co-Founder & Chief Innovation Officer at Synexa Life Sciences said: "Synexa is proud to join the CLN, bolstering CEPI’s network in the Global South and aligning ourselves with the mission of epidemic preparedness and innovation. We are excited to contribute to this global effort to combat emerging infectious diseases and protect lives worldwide. Together, we can accelerate the development and equitable distribution of vaccines, ensuring that vulnerable populations have access to life-saving interventions. Joining the CLN allows us to harness the power of collaboration, innovation, standardization, and solidarity, as we work towards a healthier, safer future for all." Emile Lens, CEO of Synexa Life Sciences commented: "Joining CEPI symbolizes the strides Synexa has made over the last decade to become an influential, global player in the biomarker and biopharma industry. We look forward to aligning our resources and leading bioanalytical expertise with the CEPI CLN to leverage collective knowledge and aid the development and deployment of life saving vaccines all over the world". About Synexa Life Sciences For over two decades Synexa Life Sciences has supported biopharma clients across the globe to achieve their clinical milestones through the application of cutting-edge biomarker science. Synexa specialises in the development, validation and delivery of a wide range of complex and custom-designed assays, founded on deep expertise in immunology and the impact of the immune system on human health and candidate drug performance. Synexa is backed by Gilde Healthcare, a leading European healthcare investor. About CEPI CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched in 2017, to develop vaccines against future epidemics. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. Waters Corporation Named to U.S. News & World Report's 2023-2024 Best Companies to Work For Story source/Credit: Waters Corporation .S. News & World Report, the global authority in rankings and consumer advice, has named Waters Corporation one of the 2023-2024 Best Companies to Work For. Waters was ranked among 200 companies on factors contributing to job seekers' decision-making when choosing a workplace that best meets their needs. The inaugural list evaluated companies based on how well they meet workers' expectations, with measures including quality of pay and benefits, work-life balance and flexibility, job and company stability, physical and psychological comfort, belongingness and esteem, and career opportunities and professional development. Waters is one of just three Life Sciences Tools companies named to the list and one out of 22 named within the broader Healthcare industry. "This recognition is a true testament to our employees and the passion they share to create an inclusive culture that unites colleagues around a greater purpose," said Dr. Udit Batra, President & CEO, Waters Corporation. "It is an honor to be recognized by U.S. News & World Report as a company that works to meet the needs of our employees so that together we can solve problems that matter, ensuring we all leave the world better than we found it." U Product Launches
Microbioz India, July 2023 | 59 "Choosing a company to work for is a big decision and there are many factors to consider during the job seeker's decision-making process," said U.S. News Senior Editor, Consumer Advice, Antonio Barbera. "The 2023-2024 list includes companies that score highest on a variety of metrics that contribute to a positive work environment and day-to-day employee experience." With more than 8,200 colleagues across 35 countries, employees at Waters are encouraged to bring their authentic selves to work each day along with their unique ideas, experiences, and thoughts, knowing they will be valued and included. Waters is dedicated to supporting employees as they achieve success at work and beyond — realizing rewarding careers, healthy lives, and bright futures. In addition to being listed on the U.S. News Best Companies to Work For, Waters has recently been recognized for its corporate sustainability progress by other leading organizations. Waters has been named to the Dow Jones Sustainability North America Index (DJSI); was listed fifth in Barron's Top 100 Most Sustainable Companies 2023; was tenth-ranked among Healthcare and Life Sciences companies in the Newsweek 2022 list of Most Responsible Companies; and was recognized in the 2022 Human Rights Campaign Corporate Equality Index as one of the Best Places to Work for LGBTQ+ Equality. To calculate the U.S. News Best Companies to Work For list, U.S. News only considered companies that were a part of the Russell 1000 index as of June 2022 and had more than 75 Glassdoor reviews written in 2022. The methodology, developed with the support of a panel of six experts, also factors in data, including employee sentiment, gathered from U.S. News partners Revelio Labs and ESG Book. About Waters Corporation Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With more than 8,200 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. About U.S. News & World Report U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities. A multifaceted digital media company with Education, Health, Money, Travel, Cars, News, Real Estate, Careers and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C. New Reliable Automatic Capper for Single Screw Cap Tubes Story source/Credit: AFYS3G BV FYS3G launches a new capping solution for the automatic closing of single sample tubes: the AFYS3G Capper for Screw Cap Tubes Sigma STR. The Sigma STR is designed to improve efficiency and can be used as stand-alone device. The Capper for single Screw Cap Tubes is a reliable and durable instrument for any lab managing compound libraries or biological sample stores that wants to increase sample throughput and reduce manual errors. Benefits of the Sigma STR The single tube capper, Sigma STR, is compatible with labware from a variety of brands like Sarstedt, Micronic, Azenta and Greiner Bio-one and can cap a single tube in 7 seconds. A Product Launches
Microbioz India, July 2023 | 60 Through the graphical touch screen interface, the operator can select different options that make capping easier, like seeing the number of capped tubes and manually change the parameters. The capper uses a precisely determined torque value for optimal sealing quality thereby minimizing evaporation and maximizing the integrity of valuable samples. Because of the large cap holder at the top of the Sigma STR, the machine can hold up to 500+ caps. This makes continues capping easy. About AFYS3G At AFYS3G our passion is to use our skills, knowledge, and experience to improve the precision and flexibility of life science research. We do this by keeping 3Goals in focus as we develop solutions: Enhance performance, empower integration and Ensure compatibility. AFYS3G is a team of enthusiastic and creative engineers who are engaged in the design, development and production of laboratory consumables and benchtop equipment related to working with samples. Whether for endusers or for third parties, we can do it. Mastering repeatability in cell culture with INTEGRA Biosciences’ WELLJET peristaltic pump dispenser Story source/Credit: INTEGRA Biosciences AG WELLJET: your trusted partner for cell-based techniques NTEGRA Biosciences’ WELLJET reagent dispenser and EasySnap™ dispensing cassettes offer a unique solution to common issues in cell-based workflows, employing peristaltic pump technology for gentle dispensing to minimize shear stress on fragile cell samples and maintain high viability. Cell culture is a powerful tool to study complex biological processes, and is an important process in pharmaceutical research, development and manufacturing. The WELLJET dispenser’s peristaltic pump technology helps to maintain cell viability by providing gentle dispensing with low shearing forces. In addition, the liquid remains enclosed inside the pump tubing system, inherently preventing sample contamination for more reproducible and reliable results. I Product Launches
Microbioz India, July 2023 | 61 Dispensing speeds and volume can be adjusted to optimize each experiment for the best possible results, while an optional dispenser stacker allows scientists to automate plate filling for higher sample throughput and reduced manual variability; the WELLJET dispenser and dispenser stacker offer the smallest footprints for instruments of their kind, saving valuable bench space and allowing the instruments to be placed into a laminar flow cabinet. The WELLJET is specifically designed for filling or adding reagents to microplates, offering full flexibility for dispensing into all microplate formats, from 6 to 1536 wells. Lidded cell culture plates can be quickly and reliably processed without manual intervention using the stacker’s lid-handling functionality. The system uses easy-to-install EasySnap dispensing cassettes, which feature injection-molded silicone tubing designed to maintain a constant inner diameter for a high degree of precision and accuracy. The cassettes can be rapidly changed between different experiments, and can be easily sterilized by flushing with 70 percent ethanol or autoclaving. These features make the combination of the WELLJET and EasySnap cassettes a valuable laboratory tool to help researchers increase productivity and streamline their cell culture workflows. Visit the INTEGRA Biosciences website to learn more. Scitara joins AWS partner network in recognition of its potential for digital transformation in the lab Story source/Credit: Scitara A New Vision of Digital Transformation aboratory digital transformation pioneer Scitara has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) partner network with its Digital Lab Exchange DLX™ cloud platform. The two organizations are now also embarking on a collaboration to develop next-generation products to drive digital transformation in the lab. The first iPaaS for Science, Scitara DLX connects every instrument, application, and resource in the lab to support data flow and compliant data management throughout the enterprise. The Scitara platform is now available on AWS marketplace, having undergone a rigorous review and assessment by the cloud computing giant. L Product Launches
Microbioz India, July 2023 | 62
Microbioz India, July 2023 | 63
Microbioz India, July 2023 | 64 PUBLISHED ON: 25th July 2023 RNI NUMBER: UPENG/2017/73675